A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Eisai Inc
- 15 Dec 2017 Planned End Date changed from 1 Mar 2016 to 30 Mar 2018.
- 20 Apr 2015 Planned End Date changed from 1 Aug 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 21 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.